GGrantIndex
Sort

82,697 grants matching vaccine development

Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies

$4,149,892
John P Moore · Weill Medical Coll Of Cornell Univ · P01 · FY2022 · AI

Basic and Applied Studies in Development of an AIDS Vaccine

$4,139,375
Marjorie Robert-Guroff · Basic Sciences · Z01 · FY2007 · CA

Project 1 – Development of Orally Bioavailable beta-CoV Inhibitors

$4,139,330
Richard K. Plemper · Emory University · U19 · FY2022 · AI

Infectious Diseases Fellowship Program

$4,138,603
Christa Zerbe · National Institute Of Allergy And Infectious Diseases · ZIE · FY2023 · AI

Harvard University Center for AIDS Research

$4,137,237
Bruce D Walker · Harvard University · P30 · FY2015 · AI

HIV Monoclonal Antibody Studies

$4,135,637
Julie E. Ledgerwood · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI

HIV Vaccine Studies

$4,135,637
Julie E. Ledgerwood · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI

Optimizing the Immunogenicity of MVA-Based AIDS Vaccines

$4,133,290
Emory University · U19 · FY2004 · AI

Global innate immune responses to HIV-1 infection

$4,132,294
Sumit K Chanda · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2014 · AI

Clinical Trials Units for NIAID Networks (UM1)

$4,132,035
Ian Matthias Sanne · Wits Health Consortium (Pty), Ltd · UM1 · FY2019 · AI

Center for AIDS Research at Emory University

$4,129,580
Carlos Del Rio · Emory University · P30 · FY2019 · AI

UAB Center for AIDS Research

$4,129,317
Michael S. Saag · University Of Alabama At Birmingham · P30 · FY2011 · AI

UCSF HIV Clinical Trials Unit

$4,128,866
Diane V Havlir · University Of California, San Francisco · UM1 · FY2013 · AI

Pre-clinical Vaccine Development for Emerging and Re-emerging Infectious Diseases

$4,122,850
John Mascola · National Institute Of Allergy And Infectious Diseases · ZIC · FY2020 · AI

HIV Preventive Vaccine Studies

$4,122,073
Barney Graham · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI

Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components

$4,121,081
Sandra D. Comer · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc · UG3 · FY2018 · DA

Smallpox subunit vaccine in the C-PERL expression system

$4,118,394
Chesapeake Perl · UC1 · FY2005 · AI

HIV Prevention Trials Network: Network Laboratory

$4,116,871
Susan H Eshleman · Johns Hopkins University · U01 · FY2009 · AI

Determinants of HIV Transmission

$4,112,421
Susan Little · University Of California, San Diego · P01 · FY2009 · AI

Operations and Management support component

$4,111,098
Barton F Haynes · Duke University · UM1 · FY2014 · AI

BREAD: Toward Development of a Vaccine for Contagious Bovine Pleuropneumonia (CBPP)

$4,110,805
Sanjay Vashee · J. Craig Venter Institute, Inc. · · FY2011 · BIO

Phase I HIV vaccine trial with DNAALVAC-HIV gp120 delta V1 vaccines

$4,110,031
Genoveffa Franchini · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

COVID-19 Clinical Support and Research

$4,108,341
Adrian McDermott · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

SHIV Env-antibody coevolution as a molecular guide to HIV-1 V3 glycan targeted vaccine design

$4,104,830
George M Shaw · University Of Pennsylvania · P01 · FY2023 · AI

Bridging Antibody Fc-mediated Antiviral Functions Across Humans and Non-human Primates

$4,104,799
Georgia D Tomaras · Duke University · P01 · FY2020 · AI